Risperidone and paliperidone inhibit p-glycoprotein activity in vitro (Q48435526)

11 February 2018

title

Risperidone and paliperidone inhibit p-glycoprotein activity in vitro (English)

1 reference

11 February 2018

1 reference

Hao-Jie Zhu

1

1 reference

11 February 2018

Jun-Sheng Wang

2

1 reference

11 February 2018

John S Markowitz

3

1 reference

11 February 2018

Jennifer L Donovan

4

1 reference

11 February 2018

Bryan B Gibson

5

1 reference

11 February 2018

C Lindsay DeVane

6

1 reference

11 February 2018

language of work or name

English

0 references

publication date

23 August 2006

1 reference

11 February 2018

published in

Neuropsychopharmacology

1 reference

11 February 2018

volume

32

1 reference

11 February 2018

issue

4

1 reference

11 February 2018

page(s)

757-764

1 reference

11 February 2018

Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301181

7 January 2021

Plasma concentrations of risperidone and its 9-hydroxy metabolite and their relationship to dose in schizophrenic patients: simultaneous determination by a high performance liquid chromatography with electrochemical detection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301181

7 January 2021

Role of transport proteins in drug absorption, distribution and excretion

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301181

7 January 2021

A fluorometric screening assay for drug efflux transporter activity in the blood-brain barrier

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301181

7 January 2021

Does inhibition of P-glycoprotein lead to drug-drug interactions?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301181

7 January 2021

Functional expression and localization of P-glycoprotein at the blood brain barrier

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301181

7 January 2021

Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301181

7 January 2021

In vitro P-glycoprotein affinity for atypical and conventional antipsychotics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301181

7 January 2021

Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301181

7 January 2021

The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301181

7 January 2021

P-glycoprotein expression in human, mouse, hamster and rat hepatocytes in primary culture.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301181

7 January 2021

The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301181

7 January 2021

Identification of P-glycoprotein in renal brush border membranes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301181

7 January 2021

Drug-drug interaction mediated by inhibition and induction of P-glycoprotein

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301181

7 January 2021

Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301181

7 January 2021

Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301181

7 January 2021

Communication between multiple drug binding sites on P-glycoprotein

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301181

7 January 2021

Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301181

7 January 2021

Impact of drug transporter studies on drug discovery and development

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301181

7 January 2021

Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301181

7 January 2021

Ontogeny of renal P-glycoprotein expression in mice: correlation with digoxin renal clearance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301181

7 January 2021

Increased drug delivery to the brain by P-glycoprotein inhibition

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301181

7 January 2021

Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301181

7 January 2021

Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301181

7 January 2021

An update of fast-off dopamine D2 atypical antipsychotics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301181

7 January 2021

Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301181

7 January 2021

New approaches to in vitro models of blood-brain barrier drug transport.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301181

7 January 2021

Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301181

7 January 2021

Population pharmacokinetic analysis of drug-drug interactions among risperidone, bupropion, and sertraline in CF1 mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301181

7 January 2021

The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301181

7 January 2021

Brain penetration of methadone (R)- and (S)-enantiomers is greatly increased by P-glycoprotein deficiency in the blood-brain barrier of Abcb1a gene knockout mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301181

7 January 2021

Olanzapine penetration into brain is greater in transgenic Abcb1a P-glycoprotein-deficient mice than FVB1 (wild-type) animals

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301181

7 January 2021

Inhibition of P-glycoprotein by newer antidepressants

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301181

7 January 2021

Identifiers

DOI

10.1038/SJ.NPP.1301181

1 reference

11 February 2018

release_2drfwgh7qbg6xnclzvpg2l5ynm

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/2drfwgh7qbg6xnclzvpg2l5ynm

24 November 2022

mapped directly with Wikidata item

1 reference

11 February 2018